In consultation with Consulting Editor, Dr. Helen Boucher, Dr. Mossad has created an issue that provides a very current look at the prevention of infections in the solid organ transplant patient. Top authors in the field have contributed clinical reviews on the following topics: Is this organ donor safe; Immunization of solid organ transplant candidates & recipients; Safe living following solid organ transplantation; Strategies for Antimicrobial Stewardship in solid organ transplant recipients; Multi drug resistant bacterial infections in solid organ transplant candidates and recipients; Yeast infections in solid organ transplant recipients; Mold infections in solid organ transplant recipients; Endemic mycoses in solid organ transplant recipients; Prevention and treatment of cytomegalovirus infections in solid organ transplant recipients; Management of BK polyomavirus infection in kidney & pancreas transplant recipients; Prevention and treatment of clostridium difficile-associated diarrhea in solid organ transplant recipients; Management of viral hepatitis in solid organ transplant recipients; Prevention and management of tuberculosis in solid organ transplant recipients; Management of mycobacteria other than tuberculosis in solid organ transplant recipients; Management of strongyloidiasis in solid organ transplant recipients; and Transplantation in HIV infected patients. Readers will come away with the clinical information and evidence they need to improve outcomes of the organ transplant patient.

In this issue, guest editors bring their considerable expertise to this important topic. - Contains 14 practice-oriented topics including COVID-19 prevention in organ transplant recipients; COVID-19 management in organ transplant recipients; updates in molecular diagnostics in organ transplant recipients; updates in immunizations for organ transplant recipients; data that inform "low hanging fruit antimicrobial stewardship interventions among solid organ transplant recipients; and more. - Provides in-depth clinical reviews of transplant-related infections, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In collaboration with Consulting Editor Dr. Helen Boucher, Drs. Aruna Subramanian and Dora Yuk-Wai Ho have created an extremely timely and relevant issue for infectious disease physcians, as the field of biologics is exploding. These new agents are being used in rheumatologic diseases, hematologic malignancies, solid tumors, and other conditions; there is a lack of guidance in the literature on how to address their infectious risks. The first 9 articles explain the mechanisms of action of the biologic agents and the infectious disease risks associated with their immune system targets. The last few articles go into more depth on the viral, fungal, and mycobacterial infections that are potentiated by biologics, and discuss recommended prophylaxis and preventative strategies, including vaccinations. Specifically, articles are devoted to the following: TNF inhibitors; Agents targeting B cells; Agents targeting T cell activation; Direct T cell inhibition and agents targeting T cell migration and chemotaxis; IL-1 and IL-6 and other interleukin and IgE inhibition; Check-point inhibitors; Tyrosine kinase inhibitors for heme malignancies; EGFR inhibitors and other Tyrosine kinase inhibitors for solid tumors; Targeting JAK-STAT signaling and complement pathway for inflammatory diseases; Viral infections Potentiated by Biologics (and Prophylaxis); Endemic Fungal Infections Potentiated by Biologics (and prophylaxis); Mycobacterial Infections Potentiated by Biologics; and Vaccinations for patients on biologics. Readers will come away with the clinical overviews of these topics to improve prevention and management of patients treated with biologics.

Fungal Infections, An Issue of Infectious Disease Clinics of North America, E-Book

In this issue of Infectious Disease Clinics, guest editors Rachael Lee and Helen W. Boucher bring their considerable expertise to the topic of Lung Infections. Top experts in the field provide important updates on hot topics such as Viral Pneumonias, Infectious Pulmonary Diseases,Infections in Heart and Lung Transplant Recipients, and more. - Contains 12 practice-oriented topics including Opportunistic Infections Post-Lung Transplantation: Viral, Fungal, and Mycobacterial; Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis; Coronavirus Disease-2019 in the Immunocompromised Host; Novel and Rapid Diagnostics for Common Infections in the Critically Ill Patient; and more. - Provides in-depth clinical reviews on lung infections, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

With collaboration of Consulting Editor Dr. Helen Boucher, Guest Editor Dr. Henry Chambers has assembled expert authors to provide current clinical reviews on the diagnosis and treatment of soft tissue and skin infections. Articles are specifically devoted to the following topics: Mimics of Skin and Soft Tissue Infections; Cellulitis; Staphylococcal Skin and Soft Tissue Infections; Necrotizing Fasciitis, Clostridial Skin and Soft Tissue Infections, and Streptococcal Toxic Shock Syndrome; Skin Infections from Bites; Skin and Soft Tissue Infections in Intravenous Drug Users; Gram-negative Skin and Soft Tissue Infections; Skin and Soft Tissue Infections in Diabetics; Skin and Soft Tissue Infections in Non-HIV Immunocompromised Hosts; Approach to the Patient with a Skin and Soft Tissue Infection; and Decolonization of Staphylococcus aureus. Readers will come away with the clinical information needed to improve outcomes in patients with soft tissue and skin infections.

There have been major advances in new therapies, diagnostic tools, and strategies for treatment and prevention of fungal infections. Despite these encouraging developments, large numbers of patients are at risk for infectious diseases, and the epidemiology of invasive mycoses continues to emerge. The diagnosis of these infections remains difficult, and treatment outcomes in highly immunosuppressed patients remain poor. Thus, this issue is devoted to state-of-the-art updates on fungal infections by internationally recognized authorities in this field. Some topics covered are Antifungal agents; State-of-the-art culture, identification, and resistance testing of fungal pathogens; Non-culture diagnostics in fungal disease; Contemporary strategies in the prevention and management of fungal infections; Invasive candidiasis; Invasive aspergillosis; Mucormycoses; and Cryptococcosis to name a few.

The potential etiologies of infection are diverse and these infections can often progress rapidly in SOT patients. Diagnosis can be difficult, owing to the altered anatomy that sometimes follows transplant surgery. Many of the areas related to infections in SOT recipients are unresolved and controversial, and recognized emerging issues include donor-derived infection, the impact of pandemic influenza in the SOT recipient, and drug-resistant infections.

In consultation with Consulting Editor, Dr. Helen Boucher, Drs. Zumla and Hui have assembled an excellent clinical overview of the current priorities in treating emerging and re-emerging infections. A number of landmark events have occurred in the area of epidemic infections. The frequency and diversity of serious and drug/antibiotic-resistant infections are increasing. New and re-emerging infectious disease outbreaks continue to cause much human suffering and loss of life worldwide. Current priority infectious diseases concerns that threaten global health security are covered in this issue: Cholera; Typhoid and antibiotic-resistant strains; multi—drug-resistant Tuberculosis; Invasive Meningococcal disease; Invasive Pneumococcal disease; antibiotic-resistant bacterial, viral, and protozoal infections; diphtheria; pandemic influenza; MERS; SARS; Measles; viral haemorrhagic fevers; wild-type Polio virus; Zika; antibiotic-resistant sexually transmitted diseases; drug-resistant Malaria; ARV-resistant HIV; and fungal infections. This issue’s clinical review articles, written by authoritative and renowned experts in the area would, have broad appeal, from general internists to respiratory specialists. It should also prove interesting to infectious diseases specialists, health practitioners in the tropics, pulmonologists, internal medicine fellows, family physicians, and health-care policy makers in the west and developing countries. Medical students, postgraduates, and research fellows (both undergraduates and postgraduates) will also find this issue useful and to be a updated reference in the field of respiratory medicine, tropical medicine, and infectious diseases.

The field of HCV has changed perhaps faster than any other field in medicine. The Guest Editors have strived to create an issue that is a state-of-the-art analysis of solutions to specific challenges faced in the United States and globally in implementing HCV elimination strategies. They believe that clinicians now have the tools and road maps needed to accomplish this goal. The clinical review articles in this issue accomplish that: Using Existing Health Care Infrastructure To Expand HCV Care; Creating A Reproducible Health Economic Model To Describe The Burden Of HCV And Cost Of Treatment In Any Country; The Best Uses Of Cost-Effectiveness Models In HCV; Increasing Access To HCV Care In Corrections; Cure As Prevention Strategies For HCV In People Who Inject Drugs; Australia Will Eliminate HCV – How It Works; New York Is The First State In The US To Develop An HCV Elimination Strategy; When HCV Diagnostics Are The Barrier To Care; Key Findings From The Checs HCV Cohort Study; Strategies To Reduce HCV Reinfection Rates In People Who Inject Drugs; Strategies To Reduce HCV Reinfection Rates In Men Who Have Sex With Other Men; The Value Of Curing HCV From A Payer’s Perspective; How To Expand Care Capacity In HCV; Strategies To Eliminate HCV In The HIV Coinfected Population; and The US Veteran’s Administration: Lessons Learned And Best Practices For HCV Elimination.